191 related articles for article (PubMed ID: 26216709)
1. Lessons learned from studies with the growth hormone receptor.
Kopchick JJ
Growth Horm IGF Res; 2016 Jun; 28():21-5. PubMed ID: 26216709
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
3. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone receptor antagonists therapy for acromegaly.
Parkinson C; Trainer PJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
[TBL] [Abstract][Full Text] [Related]
5. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR.
Lan H; Li W; Li R; Zheng X; Luo G
J Clin Endocrinol Metab; 2019 Jun; 104(6):1887-1899. PubMed ID: 30602026
[TBL] [Abstract][Full Text] [Related]
6. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
7. Insights from growth hormone receptor blockade.
Muller AF; van der Lely AJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
[TBL] [Abstract][Full Text] [Related]
8. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
9. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
11. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
12. [Growth hormone-receptor antagonist pegvisomant].
Herrmann BL; Strasburger CJ
Dtsch Med Wochenschr; 2004 Oct; 129(44):2356-8. PubMed ID: 15497105
[No Abstract] [Full Text] [Related]
13. Metabolic effects of GH antagonism in patients with acromegaly.
Trainer PJ
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
[TBL] [Abstract][Full Text] [Related]
14. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
15. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
18. Pegvisomant Pfizer/Sensus.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
[TBL] [Abstract][Full Text] [Related]
19. Place of pegvisomant in acromegaly.
Ho KK
Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
[No Abstract] [Full Text] [Related]
20. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
